Combining Biomarkers for Immunotherapy.
A biomarker analysis involving the largest dataset of its kind finds that tumor mutational burden and T cell-inflamed gene expression profile can independently predict a patient's response to pembrolizumab. However, joint consideration of both biomarkers offers the greatest clinical utility and identifies patterns of underlying, targetable biology.